In 2013, Zentiva, a unit of French pharmaceutical group Sanofi, reported net profit of RON37.2 million.
The company’s sales revenue increased 66.5% last year, to RON395.8 million, from RON237.7 million in 2013.
“We registered a growth of 30% in local production, to a total volume of 62 million commercial units,” said Christophe Gourlet, Chairman of Zentiva’s Board.
The production growth fueled a significant rise in exports, which came to account to 40% of the local plant’s sales, Gourlet added.
Sanofi plans to continue investments in its Bucharest-based facility, the company added.